Business Context and Reporting Period
Company: Immuron Ltd (Foreign Private Issuer)
Filing Type: Form 6-K
Reporting Period: August 2017 (Specific date: August 28, 2017)
Context: This filing reports a Public Notice issued to the Australian Securities Exchange (ASX) regarding the opening of a new clinical site to evaluate the safety and efficacy of the Company's product candidate, IMM-529, for the treatment of Clostridium Difficile Infection (CDI).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an event-based disclosure and does not contain financial statements or quantitative financial data.
Material Changes
Clinical Development Update: The Company has opened a clinical site to advance the evaluation of IMM-529 for CDI. This represents a material operational milestone in the Company's drug development pipeline.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses exclusively on the operational progress of the IMM-529 clinical trial. No financial guidance, forward-looking revenue projections, or specific risk factors were detailed in this specific text.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the specific location and capacity of the newly opened clinical site for IMM-529.
- Review the attached Exhibit 99.1 for detailed protocols regarding the safety and efficacy evaluation of IMM-529 for CDI.
- Confirm the timeline for patient enrollment and expected data readout dates associated with this new site.
- Check subsequent filings for any financial impact or funding requirements related to this clinical expansion.